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Abstract 
Purpose: To evaluate the benefits of using respiratory gating for left-sided breast cancer in 
the form of dose-sparing and biological effects to the heart and to investigate the set-up 
deviations for patients treated with respiratory gating in order to find an optimal correction 
strategy for this group of patients. 
Materials and methods: Nineteen patients treated with respiratory gating for left-sided breast 
cancer using the Real-time Position Management system (RPM, Varian Medical Systems, Inc., Palo 
Alto, CA) were retrospectively enrolled in this study. All patients had been treated with breast 
conserving surgery and no nodes were irradiated. Two CT-scans were performed for all patients 
treated with respiratory gating, one during deep breathing and one during normal free breathing. 
Since the patients had been treated with respiratory gating, structure delineation and treatment 
plans had already been made in the gated CT image set. For evaluation of the dose sparing and 
radiobiological effect, structure delineation was carried out and individually optimized treatment 
plans were created also for conventional treatment. Comparable target coverage was the main 
criteria when creating the treatment plans. The relative seriality model was used to calculate the 
cardiac mortality probability for the two treatment techniques. 
For evaluation of the set-up deviations, orthogonal kilovolt set-up images were acquired at every 
fraction for 18 patients treated with respiratory gating and 17 patients treated conventionally for 
comparison. In total, 659 images were acquired and manually matched with digitally reconstructed 
radiographs reconstructed from the CT image sets. Calculations of the set-up deviations were made 
both with no correction strategy applied and with the currently used correction strategy. The effect 
of the set-up deviation on the absorbed dose distribution was investigated by simulations in the 
treatment planning system (Eclipse version 10, Varian Medical Systems, Inc., Palo Alto, CA) and 
measurements with a biplanar diode array. 
Results: The mean absorbed dose to the heart was decreased for all patients in this study using 
respiratory gating. The average mean absorbed dose to the heart was 2.6 Gy for conventional 
treatment and 1.4 Gy for respiratory gating, a reduction of 46 %. For the left anterior descending 
(LAD) coronary artery  the average mean absorbed dose was 13.9 Gy for conventional treatment and 
4.2 Gy for respiratory gating, a reduction of 70 %. These reductions are statistically significant 
(p<0.01). The average mean absorbed dose to the left lung was 5.8 Gy for both conventional 
treatment and respiratory gating. As a result of the dose sparing for the heart the cardiac mortality 
probability could be reduced from 0.58 % for conventional treatment to 0.05 % for respiratory 
gating. 
An overall mean systematic deviation (moverall), calculated as the mean deviation for all patients and 
all treatment fractions, of 6.0 mm in the anterior direction and 8.1 mm in the cranial direction was 
present for the patients treated with respiratory gating if no correction strategy was applied. This 
set-up deviation results in increased absorbed dose to the organs at risk (OAR) and affects the 
absorbed dose distribution to the target. If the currently used correction strategy was applied to the 
deviations, moverall was reduced to 1.1 mm in the anterior direction and 3.3 mm in the cranial 
direction. moverall can be further reduced if the AML factor is excluded from the current correction 
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strategy. If this was done, the moverall was 0.5 mm in the posterior direction and 1.0 mm in the cranial 
direction. No difference in the random set-up error was seen between the patients treated with 
conventional treatment and respiratory gating. 
Conclusions: Significant dose-sparing to the heart and LAD can be achieved using respiratory gating 
without compromising the target coverage. As a result of this dose sparing, the cardiac mortality 
probability can be reduced. This was comparable with earlier results [10, 13]. If no correction 
strategy is used for respiratory gating large systematic set-up deviations will be present which would 
increase the absorbed dose to the OARs and affect the dose distribution to the PTV. By excluding the 
AML factor from the currently used NAL correction strategy, the set-up deviations for the patients 
treated with respiratory gating will be minimized. 
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A popularized summary in Swedish: 
Strålbehandling under inandning 
minskar bestrålningen av hjärtat – om 
patienten positioneras rätt 
Strålbehandling kan användas för att behandla olika cancerdiagnoser. Man vill då kunna rikta 
strålningen mot tumören medan så lite frisk vävnad som möjligt bestrålas. Olika studier visar att för 
patienter som behandlas med strålbehandling för cancer i vänster bröst är förekomsten av och 
dödligheten i olika hjärtsjukdomar högre än för de som behandlas med strålbehandling för cancer i 
höger bröst. Detta beror på den ökade stråldosen till hjärtat vid behandling av cancer i vänster bröst 
till följd av att hjärtat är placerat närmare vänster bröst än höger bröst. Ett sätt att minska stråldosen 
till hjärtat vid behandling av bröstcancer i vänster bröst är att använda andningsanpassad 
strålbehandling. Då får patienten andas in djupare än normalt under behandlingen efter en röst som 
säger ”andas in” och ”andas ut”. Bestrålningen sker bara när patienten andats in. Då är avståndet 
mellan bröstet och hjärtat som störst och på så sätt kan stråldosen till hjärtat minskas. I denna studie 
visas att genom att behandla patienter med vänstersidig bröstcancer med andningsanpassad 
strålbehandling kan stråldosen till hjärtat minskas med 46 %, vilket resulterar i en minskning av 
sannolikheten att dö i hjärtsjukdomar för dessa kvinnor. 
Innan strålbehandlingen får patienten göra en datortomografiundersökning, vilket är en form av 
röntgenundersökning som ger snittbilder av patienten i tre dimensioner. I dessa bilder planerar man 
sedan hur strålfälten ska gå för att få så bra fördelning av stråldosen till det område som ska 
behandlas samtidigt som man minimerar stråldosen till den friska vävnaden. Det är viktigt att 
patienten ligger likadant vid behandling som under datortomografin. Ligger patienten annorlunda 
leder det till att stråldosen inte hamnar på det område som det var tänkt vilket kan leda till 
bestrålning av riskorgan och att delar av behandlingsområdet inte får den stråldos det var tänkt. På 
grund av uppläggningsproceduren för de patienter som behandlas med andningsanpassad 
strålbehandling kommer de att ligga lite annorlunda vid varje behandling. Denna avvikelse i 
positioneringen är systematisk och påverkar samtliga tillfällen patienten behandlas och kan 
korrigeras med en korrektionsstrategi. Genom att använda en korrektionsstrategi kan man uppskatta 
den systematiska avvikelsen och korrigera för den. Om man inte använder någon korrektionsstrategi 
introducerar man stora systematiska positioneringsavvikelser genom att använda andningsanpassad 
strålbehandling, vilket påverkar dosfördelningen till behandlingsområdet och hjärtat. Det är därför 
viktigt att korrigera för dessa systematiska avvikelser. Denna studie visar att den allmänt vedertagna 
korrektionsstrategin inte är den optimala för de patienter som behandlas med andningsanpassad 
strålbehandling. En justering av denna korrektionsstrategi, som resulterar i en bättre positionering, 
föreslås istället användas för denna patientgrupp. 
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1. Introduction 
The aim of radiotherapy is to kill the tumor cells while minimize the absorbed dose to the 
surrounding healthy tissue. According to the International Commission on Radiation Units (ICRU) 
Report 50 and 62 [1,47] the gross tumor volume (GTV) contains the visible and/or palpable tumor. 
The Clinical Target Volume (CTV) contains the GTV and/or the subclinical malignant disease. The CTV 
is the volume that needs to be eradicated to achieve the aim of radiotherapy. To account for 
different uncertainties, margins are added to the CTV, creating the Planning Target Volume (PTV). 
This is done to ensure that the entire CTV receives the prescribed absorbed dose. The margins added 
to create the PTV accounts for uncertainties such as changes of the size, shape and position of the 
CTV (from for example breathing motion) and set-up uncertainties. So a common way to account for 
breathing motion of the target during radiotherapy is to add margins. Another way to account for the 
breathing motion is to use breathing adapted radiotherapy techniques (BART). Then the target is only 
irradiated in a specific part of the respiratory cycle, decreasing the margins needed to be added due 
to breathing motion. BART can also be used to increase the spatial distance between the target and 
the organ at risk (OAR), and in that way decrease the absorbed dose to the OAR. 
Breast cancer is the most common cancer among women in Sweden. In year 2010, 26 295 cancers 
were diagnosed among Swedish women according to the Swedish National board of health and 
welfare [2]. 7917 of these were breast cancer, making 30.1 % of the total diagnosed cancers among 
Swedish women. The relative five year survival of breast cancer is 87.8 % [3]. Most women treated 
for breast cancer undergo primary surgery, often followed by adjuvant radiotherapy. Surgery can 
remove any detected macroscopic disease, but some microscopic tumor foci might remain which 
could lead to locoregional recurrence or distant metastases (or both) if untreated [4]. Several studies 
show a decrease in recurrence using postoperative radiotherapy for breast cancer [4-5]. A study 
showed that the 10-year risk of recurrence decreased from 35.0 % when only treated with surgery to 
19.3 % when treated with both surgery and radiotherapy [4]. The 15-year risk of breast cancer 
mortality decreased from 25.2 % to 21.4 % when surgery and radiotherapy was used compared to 
only surgery [4]. But studies also show an increased cardiac morbidity and mortality in patients 
treated with radiotherapy for left-sided breast cancer compared to right-sided [6-9], due to the 
higher cardiac absorbed dose for the left-sided patients, implying that increased absorbed doses to 
the heart increase cardiac complications. This reduces the net benefit of the radiotherapy treatment 
for left-sided breast cancer. But if the absorbed dose to the heart could be decreased, the 
complications will decrease as well [10]. In recent years treatment such as intensity-modulated 
radiotherapy and BART have been used to decrease the absorbed dose to the heart and lungs for 
breast cancer radiotherapy [11]. Several studies using different forms of BART show a decrease in the 
absorbed dose to the heart [12-18] and to the lungs [13,15-16].  
Free breathing respiratory gating is a form of BART where the patient breathes freely, although a bit 
deeper than normal. Using an individual pre-specified gating window around the maximum of the 
breathing amplitude, the beam will be turned on only when the breast and heart are the furthest 
apart. Due to this increased spatial distance, the absorbed dose to the heart can be decreased. In the 
beginning of 2007, the radiotherapy department at SUS Malmö was the first clinic in Sweden to 
provide respiratory gating. Since then more than 700 women have been treated with this technique 
for left-sided breast cancer. 
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There are several uncertainties in radiotherapy that lead to that the absorbed dose is not delivered 
where it´s intended. One such uncertainty is patient set-up. Interfractional set-up deviations are the 
difference between a reference image (i.e. a digitally reconstructed radiograph, DRR, reconstructed 
from the CT image set) and a set-up image acquired before treatment. This deviation consists of a 
systematic and a random part [19-20], where the systematic set-up deviation affects all treatment 
fractions equally much while the random set-up deviation varies from day to day. The systematic 
part of the set-up deviation can be corrected for by an appropriate correction strategy but it doesn´t 
reduce the random part. Today, a no action level (NAL) correction strategy with an adaptive 
maximum likelihood (AML) factor is used at Skåne University Hospital (SUS) [21]. 
All patients that potentially will receive a gated treatment undergo both a conventional and a gated 
CT examination to evaluate if the patient will gain from respiratory gating or not. In association with 
the CT-scanning, skin markers are made at the patient during normal free breathing. A treatment 
plan is made on the respiratory gated CT-set but in the treatment room the patient is positioned 
during normal free breathing. This leads to a systematic deviation corresponding to the motion 
extent induced using respiratory gating for each patient respectively. This set-up deviation will then 
theoretically be present for all patients treated with respiratory gating, inducing an overall mean 
systematic deviation, moverall. This systematic set-up deviation is today thought to be captured and 
corrected for using the existing set-up correction strategy protocol.  
The aim of this master thesis is to 1) evaluate the dose sparing and radiobiological effects of 
respiratory gating by a retrospective treatment planning study, 2) investigate set-up deviations for 
the patients treated with respiratory gating and evaluate the effect of them on the absorbed dose 
distribution to the target and OARs and 3) evaluate if the existing set-up correction strategy is 
optimal for patients treated with respiratory gating. 
2. Theory 
2.1 Respiratory gating 
Breathing motion can cause the tumor to move out of the field which gives an underdosage to the 
tumor and unnecessary dose to healthy tissue. One way to avoid underdosage to the tumor is to 
increase the margins around it, but this will then increase the normal tissue irradiated. Another way 
is to account for the breathing motion by different forms of BART. Some of these techniques are 
breath hold methods, respiratory gating, forced shallow breathing and real-time tumor tracking [22-
23]. During breath hold methods the patient breathe in deep and hold his/her breath. This can be 
achieved with active techniques where a valve temporarily blocks the airflow, or with passive 
techniques, where the patient voluntarily holds his/her breath [23]. During respiratory gating the 
patient breathe freely but deeper than normal. During both breath hold methods and respiratory 
gating, the radiation beam is only on during a pre-specified part of the respiratory cycle. During 
tumor tracking the radiation beam is synchronized with the respiration and “follows” the target 
during the respiration [24]. 
At SUS Malmö respiratory gating is used for patients treated for left-sided breast cancer to reduce 
the absorbed dose to the heart. The patients are requested to breathe deeper in order to increase 
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the distance between the breast and heart. This is possible due to the fact that respiratory 
maneuvers pull the diaphragm and heart inferiorly while expanding the anterior chest wall and 
thereby increasing the distance between the breast tissue and the heart [12]. The lung mass 
irradiated will also be reduced due to the decreased lung density during deep inspiration [13,23]. 
Respiratory gating can also be used to reduce the absorbed dose to the left anterior descending 
(LAD) coronary artery, which is sensitive to radiation [25].  
During respiratory gating, radiation is only administrated in a pre-set window called the “gating 
window” (figure 1). The gating window can be placed in an arbitrary position in the breathing cycle 
depending on the aim of the respiratory gating. If the aim is to maximize the distance between the 
breast and the heart, the gating window is placed in the end-inhalation phase. There are two 
different types of respiratory gating referred to as amplitude gating or phase gating. In amplitude 
gating the radiation beam is activated whenever a certain amplitude is reached, regardless of the 
phase in the patient´s respiratory cycle. In phase gating the radiation beam is on in a certain phase of 
the respiration cycle. At SUS Malmö amplitude gating is used. The ratio of the beam-on to the overall 
treatment time is referred to as the duty cycle and is a measurement of the efficiency. Some motion 
may still occur in the gating window and this motion is referred to as “residual motion”. 
Determination of the width of the gating window is a trade of between the efficiency and the 
residual motion [22]. Using the same margins as for conventional breast treatment, the residual 
motion must not exceed the normal breathing amplitude. 
 
Figure 1 A gating curve acquired by the real-time positioning management system.  
2.1.1 Why use respiratory gating for breast cancer radiotherapy? 
Studies show an increased late cardiac morbidity and mortality for women treated with radiotherapy 
for left-sided breast cancer compared to right-sided breast cancer [6-9]. This difference is believed to 
be caused by the enhanced heart volume irradiated for left-sided breast cancer. McGale et. al. [6] 
show an increased incident ratio for left-sided breast cancer for acute myocardial infarction, angina, 
pericarditis and valvular heart disease in a study of 35 000 Swedish and Danish women treated with 
radiotherapy. The incident ratio for left-sided breast cancer patients compared to right-sided for all 
heart diseases were 1.08. Heart disease due to radiotherapy is a long-term effect, often not seen 
until more than 10 years after treatment. Darby et. al. [9] showed an increased cardiac risk with 
increasing time after diagnosis. The cardiac mortality ratio (left versus right tumor laterality) was 1.20 
less than 10 years afterwards, 1.42 10-14 years afterwards and 1.58 after 15 years or more. 
Gating 
window 
Beam on 
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According to Taylor et. al. [26], the absorbed dose to the heart has decreased over the years, owing 
to technical improvements. Due to the long time it takes to see a result on the heart disease 
incidence due to irradiation the effect from contemporary radiation techniques are not known.  
Studies have shown increased perfusion defects for LAD corresponding to the irradiated heart 
volume for left-sided breast cancer patients treated with radiotherapy [27-29].  According to a study 
by Evans et. al. [29], set-up deviations may increase the heart perfusion defects due to a larger 
volume of the heart irradiated when set-up deviations where present. A perfusion defect may result 
from the blockage of a coronary artery or from microvascular damage to an area of myocardium [25], 
but it is not yet clear what the long-term effects of these perfusion defects are. Gyenes et. al. [31] 
showed that cardiac mortality was correlated with the volume of the heart within the radiation field. 
Nilsson et. al. [46] showed an increase in stenosis in coronary arteries placed close to the breast 
(there among LAD) for patients irradiated for left-sided breast cancer compared to right-sided, which 
indicate a direct link between radiation and location of coronary stenosis. 
Several studies show an increased incidence of pneumonitis with an increased absorbed dose to the 
lungs [23,30]. Darby et. al. [9] showed a significantly higher mortality in ipsilateral than contralateral 
lung cancer for women treated with radiotherapy for breast cancer.  
These studies implies that an increased absorbed dose to the heart, LAD and the lungs can increase 
the incidence of heart and lung diseases which would reduce the beneficial effects of radiotherapy 
on overall survival.  
Studies show that techniques, such as respiratory gating and deep inspiration breath hold, for breast 
cancer reduce the cardiac volume in the radiation fields for treatment of left-sided breast cancer [12-
18]. Korreman et. al. [13] show that the median heart volume receiving more than 50 % of the 
prescription dose was reduced from 19.2 % with free breathing (FB) to 2.8 % with respiratory gating 
(RG) and 1.9 % with deep inspiration breath hold (DIBH). The median LAD volume receiving more 
than 50 % of the prescribed dose was reduced from 88.9 % with FB to 22.4 % with RG and 3.6 % with 
DIBH [13]. Some studies also show a reduction in the ipsilateral lung volume in the treatment field 
for breathing adapted treatment for left-sided breast cancer [13,15-16]. Korreman et. al. [13] show 
that the median ipsilateral relative lung volume irradiated to more than 50 % of the target dose was 
reduced from 45.6 % with FB to 29.5 % with RG and 27.7 % with DIBH. One study shows an increase 
in the absolute lung volume in the radiation field but no difference in the relative lung volume in the 
radiation fields was seen [14]. Some studies show a decrease in cardiac and lung complication 
probabilities due to this volume decrease [10,16,32]. Korreman et. al. [10] show a pneumonitis 
probability of 28.1 % with FB, 2.6 % with RG and 4.3 % with DIBH and a cardiac mortality probability 
of 3.8 % with FB, 0.5 % with RG and 0.1 % with DIBH. This means that the complication probability for 
pneumonitis and cardiac mortality were reduced with 85 % and 95 %, respectively. 
2.1.2 The Real-time Positioning Management system 
At SUS Malmö an external motion tracking system called the Real-time Positioning Management 
system (RPMTM, Varian Medical Systems, Inc., Palo Alto, CA) is used for treatment with respiratory 
gating. A plastic box containing six reflecting markers is placed on the patient’s chest (figure 2). 
Infrared light from an illuminator is reflected from the markers and detected by a camera. 
Information of the anterior-posterior movement of the box is projected real-time on a projector 
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screen, referred to as the “gating curve”. When the gating curve is within the gating window the 
radiation beam is automatically turned on (figure 1). 
 
Figure 2 The RPM camera and plastic box with the six reflective markers. The placement of the box on the 
patient’s chest. 
2.1.3 The process of respiratory gating at SUS Malmö 
At SUS Malmö there is a respiratory practice room (figure 3), where the patients can practice their 
breathing, coached by a nurse. The couch and set-up equipment in the practice room are identical to 
the ones in the CT- and treatment room. To get the desired effect it is important that the patient 
learn to breathe with her chest and not the stomach. Following a recorded voice saying “breathe in” 
and “breathe out” at selectable times, the time of inhalation and exhalation is set individually for 
each patient. These times are decided after practice to suit the patient. The patient should be able to 
breathe deeper than normal but still stable and reproducible.  
The patient is placed in the same way during the CT examination and two CT-scans are acquired, one 
during respiratory gating and one during normal free breathing. Prospective CT-scanning is used, 
meaning that the CT-slices are acquired only in a pre-set window of the respiratory cycle. Ones the 
breathing curve enters the gating window the CT-scanning starts. The gating window is placed so that 
the residual breathing motion during beam on does not exceed the breathing amplitude during 
normal free breathing. This is because the intrafraction breathing motion should not become larger 
for patients treated with respiratory gating compared to patients treated conventionally during 
normal breathing. Otherwise, the increased “blurring” of the absorbed dose distribution could cause 
underdosage to the target and overdosage to the normal tissue. A treatment plan is completed using 
the gated CT-scan. 
During treatment, the patient is positioned in the same way as during the CT acquisition and the 
marker block is placed at the same position on the chest of the patient. The gating window, 
determined at the CT session, is used and beam-on only occurs when the breathing curve is inside 
the gating window. 
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Figure 3 Respiratory practice room at SUS, Malmö 
2.2 Set-up deviations and correction strategies 
2.2.1 Systematic and random set-up deviations 
There are different uncertainties in radiotherapy that potentially can introduce a difference between 
the volume intended to be irradiated and the volume actually irradiated. To take this difference into 
account, appropriate margins are added to the CTV, resulting in a planning target volume (PTV) [1]. 
The PTV includes margins for uncertainties in organ shape and motion, beam geometry and patient 
set-up [19]. Reducing the uncertainties, the margins can be reduced and healthy tissue can be 
spared. But too small margins can lead to an underdosage of the target. In radiotherapy, deviations 
can occur between different treatment fractions (inter-fraction deviations) or during one treatment 
fraction (intra-fraction deviations). Intra-fraction deviations are caused by random patient movement 
or organ motion [19]. Organ motion is the variation of organ position and shape relative to the 
skeletal anatomy [33]. During a single treatment fraction, organ motion can be caused by breathing, 
heartbeat, swallowing and peristaltic motion. Between treatment fractions it can, for example, be 
caused by variable filling of the bladder or gastrointestinal tract and weight gain or loss.  
A patient set-up deviation is defined as the difference between the actual and intended position of 
the part of the patient which is to be irradiated [19]. The set-up deviation is measured as the 
difference between a set-up image and its corresponding reference image and will consist of both a 
systematic and a random part [19-20]. A systematic deviation affects all treatment fractions equally 
much while the random deviation varies from day to day. A good immobilization and daily set-up can 
reduce the random error but a reduction of the systematic error requires a correction [34]. Unless 
immediate, online correction of daily set up deviation is performed the best way to reduce random 
set-up deviation is by improving immobilization and set-up reproducibility [35]. In figure 4 an 
illustration of systematic and random set-up deviations are presented in the lateral and anterior-
posterior direction. Each dot in this figure represents a measurement of the patient´s treatment 
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position compared to the planned position for one treatment fraction. If there is no set-up deviation 
the dot is placed in the origo. The average position represented by the arrow displays the systematic 
deviation and the distribution of the dots around this mean value displays the random deviation. The 
systematic deviation is larger for patient 1 than for patient 2 whereas the random deviation is 
smaller for patient 1 than for patient 2. Inter-fraction set-up deviations for a whole population are 
mainly caused by mechanical shortcomings (e.g. laser misalignment), but could also be patient 
related (e.g. skin mark movement) or fixation related (e.g. patient mobility) [19]. Another major 
factor influencing the set-up uncertainty is the accuracy with which the radiation technologists are 
able to position the patient using the set-up marks. The physical and mental state of the patient also 
influences the set-up accuracy [19].  
 
Figure 4 A two dimensional example of systematic and random set-up 
deviations for two patients in the lateral and anterior-posterior direction. 
Each dot represents the patient´s position relative the planned. The arrow 
symbolizes the patient´s systematic deviation and the distribution of the 
dots the random deviation.  
 
According to van Herk [36], the random deviation has in general a much smaller effect on the dose 
distribution than the systematic deviations. The random errors give a blurring effect that leads to a 
small decrease of dose at the edge of the high dose region. The systematic errors on the other hand, 
lead to a shift that can strongly impact the dose distribution, for example if the target moves outside 
the high-dose region. Therefore it is important to correct for the systematic deviation. 
2.2.2 Calculating the magnitude of systematic and random set-up errors 
Only by acquiring multiple images the systematic and random errors can be separated. Greener [20] 
proposes a way to estimate these components and the accuracy of this approach will depend on the 
number of patients and images used in the analysis. 
The individual systematic set-up deviation for each patient, mp, is defined as the mean value of the 
deviations for all images taken for that patient, see Eq. 1. The individual systematic set-up deviation 
can differ between patients and is due to individual differences between set-up during CT and 
treatment. The individual random deviation, σrand,p, is defined as the standard deviation of the 
distribution of deviations around the mean value, mp, for that patient according to Eq. 2. This is due 
to daily variations in the set-up for the individual patient. The mean of the individual systematic set-
up deviations, i.e. the overall mean systematic deviation for all patients, is denoted moverall and takes 
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into account that different numbers of images has been acquired for different patients, see Eq. 3. If 
the value of moverall is different from zero, there is a systematic deviation present for an entire patient 
group in one direction. The systematic set-up error, Σset-up, is the standard deviation of the 
distribution of mp around the moverall for a patient population, see Eq. 4. The random set-up error, σset-
up, is the standard deviation of the individual random set-up deviations for all the patients in the 
population, see Eq. 5. Eq. 1-5 can be found in Greener´s “Practical determination of systematic and 
random set-up errors, Σset-up and σset-up, using portal imaging” [20]. Explanations of the notations in 
Eq. 1-5 are found in table 1. 
Table 1 Explanation of notations in Eq. 1-5 
Symbol Explanation 
i Image number 
p Patient number 
µ(DRR-set-up) Deviation between the set-up image and the reference image 
np Number of images taken for patient p 
N Total number of images in the study 
P Total number of patients for which images were acquired 
mp Mean deviation for patient p for all images taken, i.e. the individual systematic 
set-up deviation for patient p in a given direction 
moverall Overall mean systematic deviation in a given direction, i.e. the average of the 
mp for all patients P 
σrand,p Individual random set-up deviation, i.e. the standard deviation of the 
distribution of the deviations µ around mp for a patient p 
σset-up The random set-up error for all patients P in a given direction, i.e. the standard 
deviation of the σrand,p distribution 
Σset-up The systematic set-up error for all patients P in a given direction, i.e. the 
standard deviation of the mp distribution 
 
Mean deviation of np measurements, i.e. the individual systematic set-up deviation for patient p: 
   
 
  
                 
     
 (1) 
 
Individual random deviation for patient p: 
        
 
    
                     
 
     
 (2) 
 
Overall mean systematic deviation for all P patients: 
         
 
 
   
    
    (3) 
 
Systematic set-up error for the patient population P: 
         
 
      
                
 
    
  (4) 
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Random set-up error for the patient population P: 
         
 
   
       
       
    
  (5) 
 
If the absolute value of            
       
  
 , where t is the constant of the t-distribution for P-1 
degrees of freedom and 95 % confidence limit, it indicates a significant overall systematic deviation 
at a 95 % confidence limit [20].This deviation arises from errors in data transfer from CT to the linear 
accelerator and should be minimized [20,34]. 
2.2.3 The no action level correction strategy and the adaptive maximum 
likelihood factor 
One way of correcting the interfractional set-up deviations is to acquire set-up images and carry out 
online-corrections at every fraction. Apart from a potentially unnecessary increase in absorbed dose 
to the patient, this online-strategy is very time consuming and therefore an offline correction 
strategy is preferred [21]. An optimal correction strategy approximates the systematic deviation and 
corrects for it as soon as possible from the treatment start. But such an offline correction strategy 
only corrects for the systematic part of the set-up error and the random part remains unchanged 
[35]. 
According to Greener [20], a general example of a correction strategy is to apply a correction of 
magnitude   , where k ≤ 1 and   is the mean set-up deviation, whenever a measured displacement 
µ exceeds a given action level. The correction of the patient set-up is then applied at the next 
fraction and may be based on measured set-up deviations from one or more images. There are 
different correction strategies clinically implemented. One that is based on the reasoning above is 
the NAL correction strategy. Then   of the first n treatment fractions is calculated and a correction of 
–   is made. According to Månsson [21] the optimum value of n to get a good approximation of the 
systematic component and a low workload is 3, which has been adopted at SUS. 
Due to the fact that a deviation contains both a systematic and a random part, a correction of the 
whole mean value might result in an overcorrection. Therefore the AML factor, k, has been 
introduced by Gluhchev [37] and Shalev et al. [38].  It is given by: 
  
        
 
        
         
      
 
According to Månsson [21] the systematic and random set-up errors are approximately equal and 
then Eq. 6 can be simplified to: 
  
 
   
     
 
At SUS a NAL correction strategy with k according to Eq. 7 is used clinically today, which is the 
optimal correction strategy according to Månsson [21]. Orthogonal kilovoltage set-up images are 
acquired before the three first treatment fractions. The average displacement, µ, is calculated in the 
vertical, longitudinal and lateral directions. If the displacement, weighted by k, is larger than an 
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action level (table 2) a permanent correction of -kµ is made. If the deviation in any direction during 
the first three treatment fractions is larger than an acute action level (table 2), an online correction 
of the whole deviation is made for that treatment fraction. But the lines marking the isocenter on the 
patient are not changed. From treatment fraction 4, set-up images are acquired once every 10th 
fractions. If the deviation is larger than an acute action level (table 2) an online correction of the 
whole deviation is made, but the lines on the patient marking the isocenter are not changed. At the 
following treatment fraction a new set-up image is taken. If the mean deviation for these two 
treatment fractions, multiplied with k, exceeds the action level for permanent correction (table 2) an 
offline correction according to the above strategy is performed and applied at the next treatment 
fraction, but now with n = 2. When an offline correction is made it is always verified with a set-up 
image. 
Table 2 Action levels for breast cancer patients at SUS Malmö 
Acute action level  
online correction fraction 1-3 
(mm) 
Acute action level  
online correction fraction 4- 
(mm) 
Action level  
permanent correction 
(mm) 
4 6 3 
3. Materials and methods 
3.1 The treatment planning study 
In a retrospective study the dosimetric benefit from respiratory gating was investigated. The 
absorbed dose to the heart, LAD and left lung with respiratory gating and conventional treatment 
was compared. 19 patients treated with respiratory gating for left-sided breast cancer using the 
RPM-system at SUS Malmö were enrolled in the study. The patients began their treatment between 
February and July 2011. They had all been treated with breast conserving surgery, and underwent 
postoperative tangential radiotherapy to the breast. No nodes were treated. The prescribed dose 
was 50 Gy and delivered in 25 fractions. 
To evaluate whether the patient will benefit from respiratory gating both a conventional and gated 
CT examination are carried out for comparison. If the patient will undergo a gated treatment, 
contouring and treatment planning is only made in the gated CT-set. To be able to compare the dose 
distributions acquired from each treatment technique, contouring and treatment planning had to be 
done also in the conventional CT-sets. 
3.1.1 Contouring 
The volumes of interest (VOI) in this study were the heart, LAD, left lung, PTV and CTV and these 
were only contoured in the gated CT for the patients treated with respiratory gating. To delineate the 
corresponding structures (except the left lung) in the CT-set acquired during normal free breathing 
the application Smartadapt (Varian Medical Systems, Inc., Palo Alto, CA) was used. Smartadapt uses 
deformable registration to deform a structure-set from one CT-set to another. By using this time 
saving application, possible differences in contouring between physicians could also be avoided. For 
all patients, however some corrections were made after the suggestion from Smartadapt. The 
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corrections were performed primarily to meet the structure set in the gated CT rather than have a 
second opinion about the delineation. Any obvious errors were corrected by the author. Most 
corrections were made for the heart and LAD and smaller corrections were made for the PTV and 
CTV. The structure-sets were then reviewed and corrected if necessary by two physicians. The left 
lung was automatically contoured in both CT-sets using the automatic delineation program 
“segmentation wizard” in the treatment planning system (TPS) (Eclipse version 10.0, Varian Medical 
Systems, Inc., Palo Alto, CA). The PTV was the whole breast and the CTV the area were the tumor was 
placed before surgery (figure 9). 
3.1.2 Planning 
The treatment plans based on the gated CT consisted of two tangential main fields and one to three 
additional fields. Multileaf collimators were used to shape the fields and either 6 and 10 MV or 6 and 
18 MV photons were used. Wedges were not used since the number of respiratory cycles will 
increase significantly as a result of the decreased dose rate during treatment. The field edge margins 
for the two main fields were 5 mm (except out in the air where larger margins were used). Based on 
the conventional CT-sets, individually optimized treatment plans, similar to the delivered plans, were 
created by the author. The first priority when constructing the treatment plans in the conventional 
CT was to have comparable coverage of the PTV as in the gated plan. This allows for direct 
comparison of OAR absorbed doses. Essential the same margins for the main fields were kept in the 
conventional plan as in the gated plan. Secondly, the Swedish national guidelines for breast cancer 
treatment with radiotherapy [39] were followed. The absorbed dose to the heart and left lung were 
minimized to the extent were the PTV coverage could be kept. Also the absorbed dose to the 
contralateral breast was minimized. In the conventional treatment plans wedges were used if 
necessary. The absorbed dose distributions were calculated using the anisotropic analytical algorithm 
(AAA) version 10.0.28 for both the gated and conventional treatment plans and the absorbed dose 
was normalized as 100 % as the mean absorbed dose in the PTV. 
3.1.3 Evaluation 
Dose Volume Histograms (DVHs) were calculated using the TPS. The following quantities were 
acquired for the heart, LAD and left lung: 
 The relative structure volume receiving more than 50 % of the prescribed dose (V50%) 
 Mean absorbed dose in Gy 
The individual difference in mean absorbed dose between the two treatment techniques for all 
patients in this study were calculated and presented as histograms. Also the average mean absorbed 
dose and V50% were calculated for both treatment techniques. The relative difference (in percent) 
between the two treatment techniques were calculated and compared. All differences in this study 
are given in percent and are calculated according to: 
                    
             
         
 
where X is a given quantity. 
Evaluation of respiratory gating – dose sparing and set-up 
Anneli Edvardsson 
16 
 
Calculations and constructions of diagrams were carried out in Microsoft Excel 2007. A paired 
Wilcoxon signed rank test was carried out in SPSS version 20 (IBM; IL) to evaluate statistical 
differences of the average mean absorbed dose and average V50% between the two treatment 
techniques. The differences between the two treatment techniques were considered being 
statistically significant if p<0.01.  
3.1.4 Radiobiological effects  
To evaluate the radiobiological effect of the differences in absorbed dose to the heart between the 
two treatment techniques, the probability for cardiac mortality was calculated using the relative 
seriality model. This has previously been used for this purpose in the literature [10,13]. The normal 
tissue complication probability (NTCP) was calculated according to the following equations [40]: 
                 
          
 
    (9) 
  
       
                   (10) 
 
where n is the number of subvolumes in the dose-calculation volume, ΔVi = Vi/V where Vi is the 
volume of subvolume in the differential histogram and V is the total volume of the organ. Di is the 
absorbed dose in each subvolume. s is the seriality factor and describes the tissue architecture and 
assumes a value between 0 and 1 (parallel and serial organization, respectively). An organ where the 
substructures are organized in series becomes nonfunctional when one substructure is damaged, 
while for a parallel organ the probability of complication depends on the fraction of substructures 
damaged. Eq. 10 describes the dose-response curve for each subvolume in which a homogeneous 
absorbed dose is assumed, while Eq. 9 describes the tissue response to an arbitrary dose distribution. 
D50 is the dose resulting in 50 % complication probability and γ is the maximum relative slope of the 
dose-response curve. The NTCP-curve for carciac mortality after radiotherapy for breast cancer 
according to Gagliardi et.al [41] can be seen in figure 5. Fitting the relative seriality models to this 
curve results in the following values of the parameters; s = 1, γ=1.28 and D50=52.3 Gy [40]. 
The calculations in this study are based on differential DVHs of the heart acquired from the TPS for 
each patient, where the absorbed dose intervals were 0.05 Gy. The center value was used for Di and 
Vi  is the volume receiving an absorbed dose in that particular interval.  
 
Figure 5 Dose response curves for cardiac mortality for 
treatment for breast cancer and Hodgin´s disease [41]. 
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3.2 The set-up study 
3.2.1 Set-up image acquisition 
From the beginning, 39 consecutive patients were enrolled in this study, 19 treated with respiratory 
gating and 20 treated conventionally. Two patients treated conventionally and two treated with 
respiratory gating were not considered having representative set-ups and were deleted from the 
study. Finally, kilovolt (kV) set-up images were acquired at each fraction for 18 patients treated with 
respiratory gating and for 17 patients treated conventionally using the on-board imager (OBI, Varian 
Medical Systems, Inc., Palo Alto, CA). While all patients treated with respiratory gating had left-sided 
breast cancer, both left- and right-sided diagnoses were represented among the patients receiving 
conventional breast-treatment. It was assumed that there were no differences in set-up 
uncertainties for patients treated for left-sided and right-sided breast cancer. All patients were 
positioned in essentially the same way, at a breastboard (Posiboard-2, Civco medical solution, IA) 
with both arms elevated above the head. The patients were either given 42.5 Gy in 16 fractions or 50 
Gy in 25 fractions. So the intention was to acquire either 16 or 25 sets of set-up image pairs for each 
patient. Due to different reasons, such as technical problems with the OBI system or heavy workload 
in the clinic at the time, some set-up images were lost or not acquired. All together 659 orthogonal 
image pairs were acquired and manually matched. 
3.2.2 Matching procedure 
The kV set-up images were manually matched with DRRs reconstructed from the CT-set. Matching 
was made by landmarks visible on both the set-up image and the DRR (figure 6). The landmarks were 
the edge of the lung, sternum, clavicle, vertebras, lung and ribs, and were delineated by an oncology 
nurse in the DRR. Different landmarks were delineated for different patients, depending on the 
visibility of these landmarks in the DRR. The deviations, µ(DRR-set-up), were obtained and online or 
offline corrections were carried out if necessary according to the correction strategy used (see 
section 2.2.3).  
The matching of the set-up images with the DRRs were either performed online by an oncology nurse 
or offline by the author. If the offline matches gave deviations of 6 mm or more the oncology nurses 
were notified and an online match was performed at the next fraction. The author and nurses used 
the same matching criteria.  
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a,   
b,   
Figure 6 Set-up images aquired with the OBI-system (a) and DRR (b). Bony landmarks are outlined in yellow 
and the lung edge is outlined in green. 
 
The anterior-posterior direction is in the rest of this thesis called vertical (vert), the superior-inferior 
direction is called longitudinal (long) and the left-right direction is called lateral (lat). The scale used 
in this thesis is based on IEC 61217 [42]. This means that the deviation, µ(DRR-set-up) is:  
 Positive/negative in the vertical direction if the patient is positioned more posterior/anterior 
during treatment then during the CT-scanning. 
 Positive/negative in the longitudinal direction if the patient is positioned more caudal/cranial 
during treatment then during the CT-scanning. 
 Positive/negative in the lateral direction if the patient is positioned more to the patient´s 
right/left during treatment then during the CT-scanning. 
3.2.3 Calculations 
The set-up deviations present if no correction strategy had been applied were calculated. Any 
correction strategy of interest could then be simulated. A NAL correction strategy combined with an 
AML factor with n = 3 and k = 0.75 (according to Eq. 7) was applied [21]. mp and σrand,p were calculated 
for each patient according to Eq. 1-2, and for both treatment techniques, moverall, Σset-up and σset-up 
where calculated using Eq. 3-5, with and without the correction strategy applied. 
Calculations and construction of diagrams were made in Excel. A student´s t-test was carried out to 
evaluate if moverall was statistically significant from zero. The individual mean deviations, mp, were 
assumed to follow a t-distribution with the standard deviation Σset-up. The number of patients in the 
study (P) was 18 (respiratory gating) and 17 (conventional treatment), making the degrees of 
freedom (P-1) equal to 17 and 16. For a 95 % confidence level (p = 0.05) and 16/17 degrees of 
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freedom, the tabulated value of t is 2.120/2.110 (43). If the absolute value of            
       
  
 
there is a statistical significant overall mean systematic deviation present.  
3.2.4 Finding the optimal correction strategy 
A way to avoid the systematic deviation introduced by using respiratory gating would be to position 
the patient during deep inspiration when the respiratory gating has started. But this would be 
inconvenient for the staff and lead to uncertainties in the set-up. Therefore some other method to 
correct for the systematic deviation has to be employed. Two possible improvements to the 
correction strategy are suggested: 
 To apply a correction based on the breathing motion extent in the vertical and longitudinal 
directions before the first treatment fraction. 
 To find an optimal value of k to use in the current correction strategy for the patients treated 
with respiratory gating. 
Correcting with the breathing motion extent is a good strategy if the individual systematic deviation, 
mp, is equal to this motion extent. To investigate this, the breathing amplitude in the vertical and 
longitudinal directions was measured by the placement of the radioopaque marker in the gated and 
conventional CT-set. The two CT-sets were registered using automatic rigid registration in the TPS. 
The rigid registration was made on the vertebraes because these were considered being fixed during 
respiration. A radioopaque marker, used to mark the reference point, was placed on the chest wall to 
measure the breathing amplitude (figure 7). The movement of the radioopaque marker was 
measured using the measuring tool in the TPS. The individual systematic set-up deviation, mp, for 
each patient was plotted against the measured breathing amplitude in the vertical and longitudinal 
directions.  
To find the optimal value of k, Eq. 6 was used to calculate new values of k for the systematic and 
random set-up error present for respiratory gating. 
a,  b,  
Figure 7 Measurement of the movement of the radioopaque marker using the rigid registered CT-images in the 
vertical direction (a) and the longitudinal direction (b) 
3.3 The effect of the systematic set-up deviation on the 
absorbed dose distribution 
The effect of the systematic part of the set-up deviation on the absorbed dose distribution to the 
target and OARs was investigated by simulations in the TPS and measurements with the biplanar 
diode array Delta4 (ScandiDos, Inc., Sweden). 
Evaluation of respiratory gating – dose sparing and set-up 
Anneli Edvardsson 
20 
 
3.3.1 Simulations in the TPS 
The effect of the systematic set-up deviation on the absorbed dose distribution to the OARs was 
investigated by shifting the isocenter of the treatment fields in the TPS, corresponding to moverall 
(table 5). This was made for the 19 patients in the treatment planning study (section 3.1). The mean 
absorbed dose to the heart, LAD and left lung and the dose received by 99 % and 1% of the PTV (D99% 
and D1%) were acquired with 1) no set-up deviations, 2) set-up deviations and no correction strategy, 
3) set-up deviations and NAL (k=0.75) and 4) set-up deviations and NAL (k=1). The average values for 
all the patients were calculated. 
3.3.2 Measurements with the Delta4 
Delta4 is a biplanar diode array containing two orthogonal detector boards (figure 8). The center-to-
center distance between the diodes is 5 mm in the central 6x6 cm2 region and 10 mm in the rest of 
the array. Six gated breast cancer treatment plans were delivered to the Delta4 using the Truebeam 
linear accelerator (Varian Medical Systems, Inc., Palo Alto, CA). Two measurements were carried out 
for each patient; one without set-up deviations and one where the uncorrected set-up deviations 
corresponding to moverall (table 5) were introduced. 
To compare the two dose distributions, a 3D gamma evaluation was carried out which takes both 
dosimetric and spatial accuracy into account. The 3D gamma value is calculated in the following way 
[44]: 
                          (11) 
 
Where    is the reference point (without set-up deviation introduced in this study) and    is the 
evaluated point (with the uncorrected set-up deviations introduced) in three dimensions.  
          
        
   
 
                
   
 (12) 
 
       and        are the reference and evaluated doses, respectively and Δd and ΔD are the 
distance to agreement (DTA) and dose difference criteria respectively. In this study the passing 
criteria Δd=2mm and ΔD=3% was used. The criteria are fulfilled if       ≤ 1. A parameter called the γ-
agreement index (GAI) is defined as the fraction of the points in a VOI fulfilling the γ criteria [45]. 
 
Figure 8 The Delta
4
 diode array 
 
Table 3 summarizes the studies in this thesis. 
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Table 3 Overview of the patient material and purposes within each study 
Study Patients Purpose 
Treatment planning study 19 patients where both 
conventional and gated CT-
scans were available 
Investigate difference in 
absorbed dose to OARs 
between respiratory gating and 
conventional treatment   
Simulations in the TPS The 19 patients from the 
treatment planning study 
Investigate the effect of the 
systematic part of the set-up 
deviation on the absorbed dose 
distribution 
Measurement with the Delta4 Six patients from the treatment 
planning study 
Investigate the effect of the 
systematic part of the set-up 
deviation on the absorbed dose 
distribution 
Set-up study 18 patients treated with 
respiratory gating and 17 
patients treated conventional 
Investigate set-up deviations 
and correction strategies 
4. Results and discussion 
4.1 The treatment planning study 
4.1.1 Dose sparing 
The breast moves anteriorly and the heart moves caudally during inhalation, increasing the distance 
between the breast and heart during respiratory gating compared to during normal free breathing. 
To clarify the results a beam´s eye views for one of the patient in this study is shown (figure 9). The 
heart is placed almost entirely out of the field during respiratory and LAD is completely outside the 
treatment field for this patient.  
a,  b,  
Figure 9 Beam´s eyes views from the medial tangential field for one of the patients in the study showing the 
CTV (pink), PTV (blue), heart (purple), LAD (pink) and left lung (green) for conventional treatment (a) and 
respiratory gating (b). 
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In figure 10 a comparison cumulative DVH is shown for the same patient, displaying the relative 
volume of the structures receiving a certain absorbed dose. A dose reduction is seen for this patient 
for the heart and LAD using respiratory gating. For this patient there is an increase in the absorbed 
dose to the left lung, but this was not the general case for all patients. 
 
Figure 10 Cumulative DVH for one of the patients in the study comparing the respiratory gating and 
conventional treatment plans for the heart, LAD and left lung 
An example of how the heart and LAD moves out of the high dose area for respiratory gating is 
shown in figure 11. 
a,  b,  
Figure 11 Dose distributions in the same transversal CT-slice for conventional treatment (a) and respiratory 
gating (b) 
 
The mean DVH for all patients, i.e. the mean of the volume for each absorbed dose step, is shown in 
figure 12. A large benefit is seen for the heart and LAD, and at the same time no difference is seen for 
the left lung. It can also be seen that on average, the target coverage is equal for the two treatment 
techniques. 
The mean absorbed dose to the heart was decreased for all patients in this study (figure 13 a) and for 
all but one patient for LAD using respiratory gating (figure 13 b). Also V50% for the heart decreased for 
all patients using respiratory gating (figure 14 a). For six patients, V50% for LAD was zero for both 
conventional and gated treatment (figure 14 b). For seven patients, LAD was entirely out of the area 
receiving 50 % of the absorbed dose and for five patients V50% was reduced to very small values using 
respiratory gating. For one patient a very small increase in the V50% for LAD was seen using 
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respiratory gating. No distinct pattern was seen for the mean absorbed dose and V50% for the left 
lung (figure 13 c and figure 14 c). For both the heart and LAD, the average mean absorbed dose and 
average V50% for all patients in this study were decreased (table 4). These decreases were statistically 
significant (p<0.01). The average mean absorbed dose was decreased by 46 % for the heart and 70 % 
for LAD and the average V50% was decreased by 86 % for the heart and 99 % for LAD. 
 
Figure 12 Mean DVH for all 19 patients in this study 
If it is assumed that the lung mass is proportional to the relative lung volume through the lung 
density, the density is uniform over the whole lung and density changes due to respiration are 
likewise uniform, the relative lung volume is more relevant than the absolute lung volume [13]. The 
relative V50% for the left lung is the same for respiratory gating and conventional treatment, implying 
that the same lung mass is irradiated for the two treatment techniques. 
a,  
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b,  
c,  
Figure 13 The mean absorbed dose for conventional treatment and respiratory gating for the heart (a), LAD (b) 
and left lung (c) 
 
Performing a treatment planning study in two different respiratory phases it is important that the 
dose calculation algorithm performs equally well for both phases. Fogliata et. al. [45] have compared 
the ability of different dose calculation algorithms to compute the absorbed dose to the lung for 
different respiratory phases (FB and DIBH). The pencil beam (PB), anisotropic analytical algorithm 
(AAA) and collapsed cone (CC) were compared, and Monte Carlo (MC) was used as benchmark. Large 
differences in the absorbed dose distributions computed for FB and DIBH were observed for the PB 
algorithm, but only small differences were observed for the AAA and CC algorithms. The reason for 
this is that lateral electron transport is taken insufficient into account for the PB algorithm, resulting 
in inaccurate calculations in heterogeneous areas, such as the thorax. A 3D gamma evaluation 
showed that the fraction of lung voxels with γ > 1 for the PB algorithm were 25 % in DIBH and 15 % in 
FB. For the AAA and CC algorithms the fractions of voxels with a value of γ>1 were 2 % in FB and 4-5 
% (AAA) and 6-8 % (CC) respectively in DIBH. This implies that the accuracy of the dose calculation 
algorithms decreases as the lung density decreases, though much less for the CC and AAA algorithm. 
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In this study the AAA algorithm was used and hence only small differences in the computed absorbed 
dose distribution should be expected between the different respiratory phases due to the dose 
calculation algorithm used. In addition, in the study by Fogliata et. al., the mean lung volume were 
increased by 75 % during DIBH compared to 58 % during respiratory gating observed in this study. 
This implies that the difference in lung density is smaller between the respiratory phases in this study 
and hence the difference in the absorbed dose distribution due to the dose calculation algorithm 
should be smaller too. According to Korreman et. al. [13] differences in the computed absorbed dose 
distributions for different respiratory phases are present using the PB algorithm. Hence more 
complex algorithms, such as the CC and AAA algorithms, should be used when performing a 
treatment planning study in different respiratory phases. 
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b,  
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c,  
Figure 14 V50% for conventional treatment and respiratory gating for the heart (a), LAD (b) and left lung (c) 
 
The reduction of V50% in percent for the heart and LAD were larger in this study then earlier published 
data [13]. However, in the study by Korreman et. al. [13] the V50%  was larger for both respiratory 
gating and conventional treatment. This difference is believed to depend on that in the study by 
Korreman et. al. [13], the target included the breast, internal mammary nodes and periclavicular 
nodes but in this study the target consisted only of the breast. This implies that the patients in this 
study, where the target only consists of the breast, may not have been the patients that benefit most 
from treatment with respiratory gating. There may be other patients in our clinic, were the nodes are 
treated, that benefit even more from gated treatment. The study by Korreman et. al. showed a 
decrease in V50%  for the left lung, which was not seen in this study. 
Table 4 The average mean absorbed dose and V50% (range) for the 19 patients in the study. Values of p for the 
Wilcoxon signed rank test. 
OAR 
Average mean absorbed dose (Gy) Average V50% (%) 
Conventional 
treatment  
Respiratory 
gating 
p 
Conventional 
treatment  
Respiratory 
gating 
p 
Heart  2.6 (1.25-4.4) 1.4 (0.85-2.5) <0.001 2.3 (0.5-5.9) 0.3 (0-1.0) <0.001 
LAD  13.9 (2.2-43.4) 4.2 (1.85-7.75) <0.001 23.4 (0-97.3) 0.2 (0-0.6) 0.002 
Left lung  5.8 (1.95-11.2) 5.8 (2.6-9.15) 0.444 8.7 (1.4-19.4) 8.7 (2.6-12.8) 0.520 
 
The changes in mean absorbed dose for each individual patient are presented as differential 
histograms (figure 15). It is shown that all patients have a decrease in mean absorbed dose larger 
than 20 % for the heart. The majority of the patients have a decrease between 50-60 %. For LAD the 
mean absorbed dose is decreased for all but one patient, and for that patient there is a very small 
increase in the mean absorbed dose. For almost half of the patients there is a reduction of 70-90 % 
for respiratory gating and for the rest of the patients there is a reduction of 10-50 %. For the left lung 
there is an increase of the mean absorbed dose between 0 – 40 % for 11 patients and a decrease of 
the mean absorbed dose between 0 – 30 % for the remaining 8 patients. The average values of the 
difference in mean absorbed dose for all patients in the study are 44 % for the heart, 52 % for LAD 
and -6 % for the left lung, where positive values imply a decrease in mean absorbed dose using 
respiratory gating. 
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a,  b,  
c,  
Figure 15 Histograms of the difference in mean absorbed dose for each individual patients for the heart (a) 
LAD (b) and left lung (c). Positive values means that the mean absorbed dose is less for respiratory gating then 
for conventional treatment. 
 
4.1.2 Radiobiological effect 
To evaluate the radiobiological effects of the dose sparing to the heart seen in section 4.1.1 the 
cardiac mortality probability for the patients in this study have been calculated using Eq. 9-10. The 
cardiac mortality probability is reduced for all patients using respiratory gating (figure 16). The 
average cardiac mortality probability is 0.58 % (range 0.05-1.69 ) for conventional treatment and 
0.05 % (range 0.00-0.29) for respiratory gating. That means, according to the model used, that the 
patients dying in heart disease as a late side effect of their radiotherapy would decrease from 58 out 
of 10 000 to 5 out of 10 000 using respiratory gating, a reduction of 91 %. The NTCP values for cardiac 
mortality is already low for the conventional treatment but can be reduced even further using 
respiratory gating. 
 
Figure 16 Cardiac mortality probability 
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In a study by Korreman et. al. [10] the reduction in average long-term cardiac mortality was 83 %, 
comparable with the results in this study. But in that study the average cardiac mortality probability 
was 5.4 % for conventional treatment and 0.9 % for respiratory gating, hence much larger than in this 
study. This is a consequence of that the absorbed doses to the heart were larger in that study 
compared to this one. 
The relative seriality model, used in this study, assumes homogeneous radiation sensitivity, which for 
an organ such as the heart could be a crude approximation [41]. In figure 5 it can be seen that the 
NTCP curve for the heart varies for radiation therapy for breast cancer or Hodgin´s disease. This is 
believed to depend on which part of the heart that is irradiated [41]. Therefore irradiation to specific 
parts of the heart, such as LAD, may have a large effect on the risk. No NTCP calculations were 
carried out for the left lung because the similarity in absorbed dose between respiratory gating and 
conventional treatment. 
This study shows a decrease in absorbed dose to the heart and LAD using respiratory gating. Due to 
the decreased absorbed dose to the heart a decrease in cardiac mortality probability was seen. But 
the direct effects of using respiratory gating still need to be investigated. No study, to our knowledge, 
has compared cardiovascular side effects in women treated with respiratory gating to women 
treated conventionally. But studies show that cardiovascular complications increase with increased 
absorbed dose to the heart [6-9] and coronary arteries [46] and therefore the absorbed dose to 
these structures should be minimized. 
4.2 The set-up study 
4.2.1 The uncorrected set-up deviations 
Evaluating the motion of the radioopaque marker in the CT-sets acquired during normal free 
breathing and respiratory gating (see section 3.2.5) it can be seen that the motion during deep 
breathing is primarily in the vertical and longitudinal directions. The motion extent induced by a deep 
inhale was defined as the measured shift of the radioopaque marker between the two CT-sets. In this 
study the shifts in the slices were the marker is seen is approximated to be the shift for the whole CT-
acquisitions. The shift was 4-16 mm in the anterior direction and 4-29 mm in the cranial direction for 
17 of the 18 patients treated with respiratory gating. For one patient no conventional CT-scanning 
was performed. In the lateral direction motion is seen in both directions but the extent is much 
smaller than in the vertical and longitudinal directions. The mean motion extent in the lateral 
direction is +0.2 mm (see section 3.2.2). Therefore the main effort of this study has been to 
investigate the systematic set-up deviation in the vertical and longitudinal directions for the patients 
treated with respiratory gating. 
For each patient and each fraction the displacement µ(DRR-set-up) was measured. The displacements 
that would have been present if no correction strategy had been applied were then calculated. These 
displacements are shown as scatter diagrams in the vertical and longitudinal directions in figure 17 
and for the lateral and longitudinal directions in figure 18. These distributions imply that the patients 
treated with respiratory gating are positioned more anterior and cranial during treatment compared 
to CT-scanning (negative shift in both the vertical and longitudinal directions). No such shift of the 
distribution is seen for the breast cancer patients treated conventionally or in the lateral direction for 
Evaluation of respiratory gating – dose sparing and set-up 
Anneli Edvardsson 
29 
 
those patients treated with respiratory gating. However, some divergent displacements are 
presented (figure 17 and 18), which are all associated with two patients. 
 
Figure 17 The uncorrected displacements for each patient and each fraction in the vertical and longitudinal 
directions 
 
Figure 18 The uncorrected displacements for each patient and each fraction in the lateral and longitudinal 
directions 
The overall mean systematic deviation, moverall, was calculated for the uncorrected values according 
to Eq. 3, and the systematic set-up error, Σset-up, according to Eq. 4 and the random set-up error, σset-
up, according to Eq.5. These results are shown in table 5 for both respiratory gating and conventional 
treatment.  
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Table 5 The result of the set-up study for both respiratory gating and conventional treatment, with and without 
correction strategies applied 
Direction 
Respiratory gating Conventional treatment 
Vert (mm) Long (mm) Lat (mm) Vert (mm) Long (mm) Lat (mm) 
 Uncorrected results 
moverall -6.0 -8.1 0.7 3.1 1.4 -1.9 
Σset-up 6.3 8.6 2.4 5.5 4.7 3.7 
σset-up 3.6 3.5 2.9 3.6 4.1 3.1 
 Corrected results, NAL k = 0.75 
moverall -1.1 -3.3 1.3 1.2 0.7 -0.8 
Σset-up 2.8 3.7 2.8 3.7 3.2 2.4 
 Corrected results, NAL k = 1 
moverall 0.5 -1.0 1.2 - - - 
Σset-up 3.0 2.5 2.2 - - - 
 
Without any correction strategy applied, the moverall is -6.0 mm in the vertical direction and -8.1 mm 
in the longitudinal direction (table 5), which implies that the patient group treated with respiratory 
gating is positioned more anterior and cranial during treatment then during CT-scanning, which is in 
consistency with what we expected when we started this study. This was not seen for the 
conventional treatment, where moverall is 3.1 mm in the vertical direction and 1.4 mm in the 
longitudinal direction. The systematic set-up error, Σset-up, is larger in the vertical and longitudinal 
directions for respiratory gating compared to conventional treatment, implying a larger spread of the 
individual systematic set-up deviation around the moverall. The random set-up errors are in the same 
magnitude for both treatment techniques, so no additional random component is induced in the set-
up using respiratory gating. 
T-tests were carried out to evaluate if moverall differed statistically significant from zero (table 6). Not 
surprisingly, for respiratory gating moverall in the vertical and longitudinal directions are statistical 
significant. It is known that the reason for this is the motion extent induced by respiratory gating 
after set-up of the patient. But that moverall for conventional treatments were statistically significant in 
the vertical and lateral directions were not expected. For the vertical direction, it could be explained 
by one patient that have very large deviation in the vertical direction, see figure 17. If this patient is 
excluded from the study, moverall in the vertical direction is no longer statistically significant. The 
statistical significant moverall in the lateral direction needs further investigation.  
Table 6 Results of the t-tests carried out to investigate if moverall differ statistically significant from zero 
Treatment technique Direction Statistical significant (p<0.05) 
Respiratory gating 
Vert Yes 
Long Yes 
Lat No 
Conventional treatment 
Vert Yes 
Long No 
Lat Yes 
 
From the results above it is clear that a correction strategy for patients treated with respiratory 
gating is needed, otherwise large systematic deviations will be present in the vertical and 
longitudinal directions. 
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4.2.2 Evaluation of the NAL correction strategy with k=0.75 
A NAL correction strategy with k=0.75 was applied to the uncorrected displacements and the results 
are presented in figure 19 and 20 for the patients treated with respiratory gating. There is still a clear 
systematic set-up deviation in the cranial direction (negative shift), implying that this correction 
strategy is not the optimal one for the patients treated with respiratory gating.  
In both the vertical and longitudinal directions and for both treatment techniques, Σset-up and  moverall 
are reduced when this correction strategy is applied (table 5). Σset-up is reduced to comparable 
magnitude for the two treatment techniques. For respiratory gating there still is a systematic 
deviation in the vertical and longitudinal directions after this correction strategy has been applied. 
The random set-up error, σset-up, is not affected by the correction strategy and is not shown for the 
corrected results. 
 
Figure 19 The displacements for each patient and each fraction in the vertical and longitudinal directions for the 
patients treated with respiratory gating, both uncorrected and corrected with NAL k = 0.75 
 
Figure 20 The displacements for each patient and each fraction in the lateral and longitudinal directions for the 
patients treated with respiratory gating, both uncorrected and corrected with NAL k = 0.75 
Looking at the individual patients treated with respiratory gating, the individual systematic 
deviations, mp, can be seen in figure 22-24. There is an undercorrection present for all patients in the 
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longitudinal direction with this correction strategy (figure 23). In the vertical direction there is an 
undercorrection present for the majority of the patients (figure 22). This is what gives rise to the 
negative values of moverall that can be seen in table 5. Due to the undercorrection seen for the 
majority of the patients, the currently used correction strategy is not the optimal one. 
The larger systematic deviation for respiratory gating also shows in the number of corrections made 
after three treatment fractions (table 7). Due to the fact that corrections are made in 78 and 72 % in 
the vertical and longitudinal directions respectively, it is very important that the correction strategy is 
the optimal one. This also implies a higher workload for the patients treated with respiratory gating. 
Table 7 Fraction of patients where a permanent correction were made after three treatment fractions 
Direction Respiratory gating (%) Conventional treatment (%) 
Vert 78 53 
Long 72 24 
Lat 11 35 
 
Set-up images are acquired also later in the treatment, according to section 2.2.3. If systematic 
deviations larger than a certain action level are seen, permanent corrections are made. This means 
that deviations not captured during the first three treatment fractions or induced later in the 
treatment can be corrected for. This is not taken into account in this study. There are strong reasons, 
however, to improve the correction strategy used for the first three treatment fractions instead: 
 Optimal correction earlier in the treatment. 
 Less workload for the staff. 
 A small systematic set-up deviation may not be captured later in the treatment if it is lower 
than the action level (table 2). 
It can be seen for some patients that deviations are present also after permanent correction, see for 
example patient 9 in the vertical direction (figure 22). Possible reasons for this deviation can be a 
different set-up when new lines are drawn compared to when the set-up images were acquired or 
that three treatment fractions were not enough to estimate the systematic part of the set-up 
deviation. To be able to detect and correct for this is another good reason to acquire set-up images 
later in the treatment. 
Due to the undercorrection seen with the currently used correction strategy for the patients treated 
with respiratory gating, it is of interest to find a better correction strategy for this group of patients.  
4.2.3 The optimal correction strategy 
Two possible correction strategies were suggested, to correct by the motion extent induced by 
respiratory gating before the first fraction and to change the value of the AML factor in the NAL 
correction strategy.  
Correction with the motion extent 
The motion extent induced by respiratory gating was measured (see section 3.2.5) and plotted 
against mp (figure 21). The solid line shows where the motion extent and mp are equal. The dashed 
lines show an interval of ±3 mm, the action level for permanent correction. The values of the motion 
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extent were used to correct all deviations and then the individual mean deviation was recalculated. 
This correction strategy gives inconsistent results, however (figure 22-23). For some patients it was a 
good approach, but for others it resulted in large deviations. Due to the inconsistency it was 
concluded that the approach using the measured breathing motion extent to correct the patient set-
up before the first treatment is not an optimal correction strategy. 
 
Figure 21 The motion extent induced by respiratory gating plotted against the individual systematic set-up 
deviation, mp, in the vertical direction (a) and the longitudinal direction (b). 
Calculation of optimal AML factor 
In figure 22-23 it is shown that the current correction strategy leads to an undercorrection in both 
vertical and longitudinal directions. For respiratory gating Σset-up=1.75σset-up in the vertical direction 
and Σset-up=2.46σset-up in the longitudinal direction, compared to conventional treatment were Σset-
up=1.51σset-up in the vertical direction and Σset-up=1.12σset-up in the longitudinal direction. Thus basing 
the value of k on Eq. 7 assuming that Σset-up= σset-up is not correct for respiratory gating, where the 
systematic and random errors are far from equal. Calculating the AML factor using Eq. 6 gives values 
of k=0.90 in the vertical direction and k=0.95 in the longitudinal direction for respiratory gating. In 
figure 22-23 the individual mean systematic deviations corrected with these values of the AML factor 
is presented. The moverall is -0.1 mm in the vertical direction and -1.8 mm in the longitudinal direction. 
Thus, it is still not an optimal value of k in the longitudinal direction. This is due to the statistically 
significant moverall present for this group of patient, making the systematic part of the set-up deviation 
much larger than the random part. 
Excluding the AML factor 
To further optimize in the longitudinal direction and to get an uncomplicated correction strategy 
usable in the clinic, the AML factor was excluded, i.e. k=1, was evaluated (figure 22-23). Using k=1, 
moverall is 0.5 mm in the vertical direction and -1.0 mm in the longitudinal direction (table 5), 
compared to moverall  equal to -1.1 and -3.3 mm respectively for k=0.75. As a compromise for both the 
vertical and longitudinal directions, and to get a correction strategy that is easy to implement in the 
clinic, the best correction strategy for the patients treated with respiratory gating is to exclude the 
AML factor.  
The systematic set-up error, Σset-up, is 3.0 and 2.5 mm respectively for k=1 compared to 2.8 and 3.7 
mm for k=0.75 in the vertical and longitudinal directions. It can also be seen that the moverall and Σset-up 
are decreased also in the lateral direction when excluding the AML factor (table 5).  
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Figure 22 The individual systematic set-up deviation in the vertical direction for all 18 patients treated with 
respiratory gating. Both the uncorrected values and corrected with different correction strategies. 
 
 
Figure 23 The individual systematic set-up deviation in the longitudinal direction for all 18 patients treated with 
respiratory gating. Both the uncorrected values and corrected with different correction strategies. 
 
 
Figure 24 The individual systematic set-up deviation in the lateral direction for all 18 patients treated with 
respiratory gating. Both the uncorrected values and corrected with different correction strategies. 
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In figure 25 cumulative histograms for no correction strategy applied, the currently used correction 
strategy and the proposed new correction strategy are presented. The cumulative histograms show 
the fraction of the patients having more or equal to a certain absolute value of the individual 
systematic set-up deviation. The narrower the distribution is, the more effective the correction 
strategy is. The narrowest distributions are seen for the NAL correction strategy with k = 1. So this 
correction strategy is more effective than the currently used one and is therefore proposed as a new 
correction strategy for the patients treated with respiratory gating, in all three directions.  
a,  b,  
c,  
Figure 25 Cumulative histograms of the individual systematic set-up deviation for different correction 
strategies for the patients treated with respiratory gating in the vertical (a) longitudinal (b) and lateral (c) 
directions. 
 
Cumulative histograms for the patients treated with conventional treatment are shown in figure 26. 
No difference in the set-up is seen between k = 0.75 and k = 1 for this patient group. A narrowing of 
the distribution can be seen using a correction strategy compared to the uncorrected result, 
especially in the vertical and lateral directions. Therefore no change of the correction strategy is 
proposed for the patients treated conventionally. 
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c,  
Figure 26 Cumulative histograms of the individual systematic set-up deviation for different correction 
strategies for the patients treated with conventional treatment. In the vertical (a) longitudinal (b) and lateral 
(c) directions. 
4.3 The effect of the systematic set-up deviation on the 
absorbed dose distribution 
4.3.1 Simulations in the TPS 
The systematic component of the set-up deviation was simulated in the TPS for the 19 patients in the 
treatment planning study (section 3.1). The average mean absorbed dose was increased from 1.38 to 
2.21 Gy for the heart, from 4.17 to 8.86 Gy for LAD and from 5.80 to 7.64 for the left lung when the 
uncorrected set-up deviations were simulated (table 8). When the two correction strategies were 
simulated the differences in the mean absorbed dose were much smaller. 
 
Table 8 Average mean absorbed dose to the OARs. The difference in percent compared to no set-
up deviation simulated in parentheses. 
 Heart (Gy) LAD (Gy) Left lung (Gy) 
No set-up deviations simulated 1.38 4.17 5.80 
No correction strategy 2.21 (60.2) 8.86 (112.7) 7.64 (31.7) 
NAL k = 0.75 1.48 (6.9) 4.53 (8.8) 6.00 (3.4) 
NAL k=1 1.31 (-5.3) 3.86 (-7.5) 5.51 (-5.1) 
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Cumulative histograms of the mean absorbed dose are shown in figure 27. An increased absorbed 
dose to the OARs is shown if no correction strategy is applied to correct for the systematic set-up 
deviation. In figure 28 it is shown that this increase in mean absorbed dose to the OARs is a result 
of both the anterior and cranial set-up deviations and that the effect on the absorbed dose to the 
PTV is mainly caused by the set-up deviation in the cranial direction. 
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a,  b,  
c,  
Figure 27 Cumulative histograms for the mean absorbed dose for the heart (a), LAD (b) and left lung (c)  
 
To avoid the impact of superficial low absorbed doses the D99% and D1% were used as metrics of the 
minimal and maximal absorbed doses to the PTV. The average value of the D99% is decreased and D1% 
increased if the uncorrected set-up deviations are simulated and unchanged if the correction 
strategies are applied (table 9). The quite small impact of the set-up deviations on the absorbed dose 
distribution to the PTV is due to the large field edge margin in the anterior direction (figure 28).  
a,  b,  
Figure 28 Beam´s eyes views for one patient in the study for no simulated set-up 
deviations (a) and with the uncorrected set-up deviations applied (b). 
 
The systematic set-up deviation will lead to an increased absorbed dose to the OARs and affect the 
absorbed dose distribution to the PTV if not corrected for. So implementing respiratory gating in the 
clinic without a set-up correction strategy, might cancel out some of the dose sparing seen in section 
4.1.1 using respiratory gating.  
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Table 9 The average value of the dose received by 99 % and 1% of the 
PTV (D99% and D1%) for all patients in this study 
 D99% (Gy) D1% (Gy) 
No set-up deviations simulated 45.9 52,6 
No correction strategy 44.5 53.4 
NAL AML = 0.75 45.9 52.7 
NAL no AML 45.9 52.7 
 
4.3.2 Measurements with Delta4 
For the measurement with Delta4, a dose deviation and DTA criteria of 3 %/2 mm were used in the 
gamma evaluation. The average GAI were 64.2 % when the uncorrected set-up deviations were 
induced compared to 97.3 % in the original treatment plan (table 10).  
Table 10 The γ-agreement index (GAI) for the measurement with delta
4
 using the criteria 3 %/2 mm 
Patient number 
GAI 
Uncorrected set-up deviation No set-up deviation 
1 60.9 99.7 
2 68.2 96.9 
3 53.6 96.6 
4 66.3 95.0 
5 66.5 99.2 
6 69.5 96.6 
Average 64.2 97.3 
 
This difference in GAI implies that the systematic set-up deviations result in a large difference 
between the two dose distributions. The measuring points using the Delta4 were compared to dose 
profiles acquired from the TPS, both with and without the uncorrected set-up deviations induced 
(figure 29). A shift in the dose profile is introduced with the set-up deviation. Good agreement 
between the measurement and the simulation in the TPS were observed.  
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a,  
 
b,  
Figure 29 Absorbed dose profile for the detector boards showing the shift in the absorbed dose distribution 
induced by the systematic set-up deviation in the vertical direction (a) and the longitudinal direction (b) for 
one patient in this study. 
5. Conclusions 
There is a significant dose sparing for the heart and LAD using respiratory gating compared to 
conventional treatment due to increased spatial distance between the breast and heart, while there 
is no difference for the left lung. The average mean absorbed dose is reduced by 46 % for the heart 
and 70 % for LAD using respiratory gating, without compromising the coverage of the target. The 
dose sparing to the heart results in reduced cardiac mortality probability.  
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A systematic set-up deviation is induced using the set-up procedure used at our clinic for patients 
treated with respiratory gating. The dosimetric consequences if this is not corrected for would be an 
increased absorbed dose to the OARs and the absorbed dose distribution to the PTV would be 
affected. Therefore it is important with a solid correction strategy using respiratory gating. 
The currently used and generally accepted NAL correction strategy with an AML factor of 0.75 leads 
to an undercorrection for most of the patients treated with respiratory gating, and is thus not the 
optimal correction strategy for this patient group. The reason for this is the systematic part of the 
set-up deviation is much larger than the random part. To exclude the AML factor, i.e. to use k = 1, 
result in an improved set-up for the patients treated with respiratory gating. 
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